Kura Oncology Inc. (KURA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±11.2% realized swing band)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While KURA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.15) and Max Pain ($11.09) forces dealer call-delta covering toward $14.60.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Kura Oncology Inc. (KURA) slipped -1.49% to $10.56, trading at 49% of its 52-week range ($7.36 – $13.9). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +25.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KURA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KURA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Kura Oncology Inc. (KURA) ranks #952 by composite RQD confidence (29/100, grade E) and #368 by equity capitalization ($939.4M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. AKTS currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with KURA at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KURA
ACTIVE
Kura Oncology Inc. | E | 29/100 | — | — | -35.0% | -1.49% | $939.4M | Benchmark Subject |
| AKTS Aktis Oncology Inc. | D+ | 56/100 | — | — | — | +0.18% | $937.2M | /akts-vs-kura → |
| ORIC Oric Pharmaceuticals Inc. | D- | 39/100 | — | — | -33.4% | -3.33% | $931.8M | /oric-vs-kura → |
| CYRX CryoPort Inc. | D- | 38/100 | 11.8x | 47.1% | -11.5% | -1.88% | $926.4M | /cyrx-vs-kura → |
| ANRO Alto Neuroscience Inc. | D- | 38/100 | — | — | -35.0% | +0.60% | $921.0M | /anro-vs-kura → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kura Oncology Inc. (KURA) reported GAAP revenue of $67.5M (+25.2% vs. FY2024 revenue of $53.9M ) , GAAP net income of -$278.7M, operating cash flow of -$64.1M, and free cash flow of -$70.7M (-152.8% YoY). On the balance sheet, KURA closed FY2025 with $738.4M in total assets against $9.7M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $67.5M | -$278.7M | -$64.1M | -$70.7M | $738.4M | $9.7M |
| FY2024 (FY) | 2024-12-31 | $53.9M | -$174.0M | $134.3M | $133.8M | $760.2M | $6.9M |
| FY2023 (FY) | 2023-12-31 | $0 | -$152.6M | -$124.8M | -$124.8M | — | — |
As of 2026-11-01, Kura Oncology Inc. (NASDAQ: KURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $10.56 (-1.49% 1D, market cap $939.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KURA ranks #952 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KURA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AKTS (Aktis Oncology Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $937.2M) and ORIC (Oric Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
Per KURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422143), Kura Oncology Inc. generated $67.5M in revenue (+25.2% YoY), -$278.7M in net income, and -$70.7M in free cash flow against $738.4M in total assets and $9.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
KURA last traded at $10.56 (-1.49% on volume of 1,590,517 shares), positioning the stock -5.29% below its 50-day simple moving average ($11.15) and +7.65% above its 200-day simple moving average ($9.81). Across its 52-week range of $7.36 to $13.90, KURA sits at the 48.9% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($9.38 to $11.74).
Why KURA Stock slipped -1.49% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.